Sébastien's picture

Sébastien Wieckowski, Ph.D.

Excellence · Integrity · Reproducibility

Education

Ph.D. in Immunology

Université Louis Pasteur Strasbourg, France
2007

M.Sc. in Health Biology (DEA Biologie-Santé)

Université Montpellier II, France
2003

Maîtrise in Biochemistry

Université Montpellier II, France
2002

B.Sc. in Biochemistry/Bioinformatics (summa cum laude)

Université Montpellier II, France
2001

Languages

  • French native
  • English proficient/fluent
  • German B1+
  • Polish conversational

Interests

  • Electronics
  • Ethical hacking
  • DIY
  • Retrogaming
  • Half-marathon
  • Tennis
  • Hiking
  • Gardening

STRATEGIC R&D LEADER AND HYBRID SCIENTIST

Multidisciplinary PhD Immunologist with over 15 years of leadership in biotech R&D. I orchestrate the full drug development value chain, spanning high-level academic discovery, cross-border corporate transformations, and late-phase clinical transitions.

I bridge the gap between biological complexity and computational integrity by leveraging applied AI, machine learning, and IT-grade biostatistics. My mission is to accelerate the discovery of next-generation therapeutics—across vaccines, biologics, and small molecules—by integrating version-controlled transparency and reproducible workflows into rigorous scientific and regulatory standards.

CORE STRATEGIC PHILOSOPHY

  • Multi-Modality Expertise: Proven track record in the development of DNA vaccines, small molecules, peptides, and complex biologics (bispecifics, immunocytokines)
  • Diverse Therapeutic Impact: Extensive R&D experience across immuno-oncology, allergy, autoimmune diseases, inflammatory disorders, and infectious diseases
  • Agile Research Settings: Successfully led programs within Big Pharma (Roche), high-growth Biotech (VAXIMM, Worg), prestigious Academic Institutes (Ludwig, CNRS), and specialized R&D Consulting
  • Computational Integrity: Architect of high-integrity Python pipelines designed to replace manual data processing with reproducible, auditable, and version-controlled discovery workflows
  • Scientific Authorship: Author of the book "Intuitive Biostatistics with Python" (Oxford University Press, 2026), establishing a new standard for data literacy in the life sciences

RESEARCH EXPERIENCE

Chief Scientific Officer (CSO) / Senior Director Platform Technologies

2024 — Present
VAXIMM — OSR Health (prev. NASDAQ / OTC: OSRH), Basel (CH) / Seoul (KOR)
VAXIMM
  • Directed technical and operational stabilization through the corporate business combination and successful public market listing on the Nasdaq, while safeguarding IP assets and aligning capital strategy to sustain pipeline valuation.
  • Leading a multi-modality R&D strategy across clinical-stage immuno-oncology programs, translating complex mechanism-of-action datasets into global regulatory milestones and board-level portfolio decisions.
  • Oversaw CMC and Quality strategy for live biotherapeutics, including the design and progression of innovative oral formulations for DNA vaccine platforms.
  • Directing an international network of internal teams and decentralized CROs/CDMOs across Europe, the US, and Asia, enforcing rigorous data integrity and GCLP translational standards.
executive leadership corporate restructuring global regulatory strategy immuno-oncology DNA vaccines oral formulation CRO/CDMO management

Founder & Principal Consultant — Life Sciences Data & Due Diligence

2023 — Present
second scight, Strasbourg (France)
second scight
  • Accredited for the French Research Tax Credit (CIR): officially recognized by the French Ministry of Higher Education & Research to provide high-level R&D consulting services with significant fiscal advantages for clients
  • Providing high-level R&D consulting and objective due diligence through a truthful examination of raw data for M&A and investment evaluations
  • Deploying applied AI and Python-based pipelines to automate experimental analysis, ensuring the highest standards of research integrity for biotech clients
data analysis biostatistics bioinformatics applied AI due diligence scientific writing reproducible research

Director Preclinical Development

2021 — 2023
Worg Pharmaceuticals, Allschwil (CH) / Hangzhou (CN)
  • Directed the preclinical lifecycle for a diverse portfolio including small molecules, peptides, and biologics
  • Established GLP IND-enabling programs for lead candidates in ophthalmology and successfully extended packages to support Phase IIa trials in autoimmune and allergy indications
  • Authored and defended critical regulatory documentation for the FDA, EMA, and CDE (China), including Investigator Brochures and CTD Modules
FDA/EMA/CDE IND-enabling PK/PD toxicology ocular toxicity nonhuman primates small molecules peptides inflammation allergy

Principal Scientist & R&D Lead

2018 — 2021
Roche / University of Applied Sciences (FHNW), Basel, Switzerland
  • Acted as a strategic consultant between R&D and Technical Development (PTDE), facilitating the transfer of human immunobiology techniques to support high-priority assets like gantenerumab and glofitamab
  • Led the transition of artisanal cell-based assays into standardized, robotic, and GMP-compliant workflows, significantly enhancing throughput and data reproducibility
GMP bioassays ADCC ADCP NK cells macrophages AAV imaging cytometry ddPCR cell & gene therapy Pentraxin-2 gantenerumab pertuzumab glofitamab

Senior Scientist & Project Lead / Neoantigen Discovery Lead

2016 — 2021
VAXIMM AG & NEC Corporation Alliance, Basel (CH) / Mannheim (DE)
VAXIMM
  • Directed R&D, nonclinical pharmacology, and toxicology for the proprietary oral bacterial DNA vaccine platform (VXM01, VXM04, VXM06, VXM10).
  • Spearheaded the co-development and clinical translation of the personalized neoantigen asset (NECVAXNEO1) in a strategic alliance with NEC Corporation.
  • Deployed machine learning workflows on patient NGS data to automate neoantigen prediction, selection, and epitope assembly.
  • Supervised GCLP clinical immunomonitoring and translational histopathology for Phase I/II oncology clinical trials (glioblastoma, pancreatic cancer) while managing global CRO networks.
  • Led business development and strategic scientific partnering initiatives across academic institutions and pharmaceutical co-developers.
cancer vaccines DNA vaccines neoantigen discovery machine learning GCLP immunomonitoring pharma alliances CRO management

Parental Leave

2015
Alsace, France

Dedicated period for family care, paired with advanced professional competencies in biostatistics, physiology, and Python programming.

childcare project management biostatistics Python self-education

Roche Postdoctoral Fellowship (RPF)

2012 — 2015
Roche Glycart / Universitätsspital Basel / DBM, Schlieren and Basel, Switzerland
  • Assessed novel tumor stroma-targeted IL-2-variant immunocytokines, combining them with immune checkpoint inhibitors in genetically engineered mouse models (GEMM) of lung cancer (Lab: Prof. Zippelius/Dr. Klein)
  • Served as Deputy Study Director for animal licenses and established high-impact collaborations with ETHZ, MGH, and CureVac
IL-2 immunocytokines immune checkpoint inhibitors lung cancer GEMM imaging (SPECT/µCT) LTK2 study director animal licenses

Lab Manager / Maître Assistant

2008 — 2012
Ludwig Institute for Cancer Research / UNIL / CHUV, Lausanne, Switzerland
  • Characterized T-cell responses in melanoma patients following therapeutic vaccination using single-cell analysis and TCR sequencing (Lab: Prof. Romero)
  • Mentored and supervised undergraduate/graduate students and technical staff in advanced laboratory techniques
TCR sequencing microarray single-cell analysis T-cell cloning ELISpot lentivirus

Visiting Scientist

2007 — 2008
Faculté de Médecine RTH Laennec, Lyon, France
  • Spearheaded a national initiative focused on the transduction of human dendritic cells using adenoviral vectors to enhance the presentation of HIV-1 epitopes
  • Orchestrated a long-term collaborative project with the Laboratory of Virology & Viral Pathogenesis, focusing on potentiating anti-HIV-1 immune responses
HIV-1 adenovirus dendritic cells molecular biology viral pathogenesis grant management

Ph.D. Researcher

2003 — 2007
Université Louis Pasteur, Strasbourg, France
  • Innovated functional CD40L mimetics utilizing C3-symmetric peptide scaffolds, working at the high-impact interface of organic chemistry and immunology
  • Served as Lab Manager within the Immunologie et Chimie Thérapeutiques group at the IBMC (Lab: Prof. Muller; Member of the French Academy of Sciences), overseeing daily operations and technical infrastructure
  • Mentored and trained a diverse group of students and technical staff in advanced laboratory techniques
CD40L peptide scaffold apoptosis SPR confocal microscopy lab management mentoring

University Instructor & Pedagogical Fellow (Immunobiology)

2004 — 2007
Université Louis Pasteur, Strasbourg, France
University of Strasbourg
  • Instructed undergraduate biochemistry cohorts in foundational immunology, laboratory techniques, and rigorous experimental design.
  • Mentored students in hypothesis testing and scientific communication, establishing the pedagogical foundation that culminated in international textbook authorship (Oxford University Press).
scientific communication pedagogy & mentoring experimental design immunology instruction

Scientific Computing & Systems Administrator

2004 — 2007
CNRS UPR9021, Université Louis Pasteur, Strasbourg, France
CNRS
  • Engineered and administered core laboratory network infrastructure, workstations, and high-availability servers to ensure continuous data availability for high-throughput instrumentation.
  • Conducted specialized computational workshops to elevate laboratory data literacy, establishing a lifelong foundation in systems engineering and reproducible digital architectures.
systems administration network engineering computational infrastructure data security

MULTIDISCIPLINARY METHODOLOGICAL AND COMPUTATIONAL EXPERTISE

Experimental and Translational Sciences
Immunology
human PBMC Ficoll serum MACS T-cell clones dendritic cells macrophages 51Cr-release BATDA CTL lentivirus pMHC multimers ELISA ELISpot multiplex immunoassays

Cell biology and imaging
flow cytometry (Fortessa, Accuri, Calibur, Array, CyAn, Gallios, Attune) imaging flow cytometry (Amnis) FACS (Ventage, Aria) intracellular staining CBA transfection RNAi cell cycle apoptosis 3D-culture confocal microscopy live imaging fluorescent IHC H&E staining cryosection AAV

in vivo pharmacology
injection (iv, sc, po, im, id, nas) intratracheal GEMMs tumor xenografts TGI survival blood sampling organ collection lymphoid tissues genotyping SPECT/μCT (Bioscan) animal licenses

Molecular biology and biochemistry
PCR ddPCR RT-PCR RNA-Seq DNA sequencing TCR spectratyping molecular cloning recombinant proteins hybridoma Southern blotting Northern blotting whole genome microarray (Agilent) SPR (BIAcore) DLS SDS-PAGE Western blot 2D electrophoresis

Advanced Computational & Data Engineering

Expert in leveraging Python (Pandas, Plotly, Scikit-learn) and Cloud (GCP) to build automated discovery tools that ensure biological data integrity and research auditability. Architect of high-performance Python pipelines and version-controlled reporting workflows, moving the laboratory environment toward IT-driven reproducibility. Expert in designing (sc)RNA-Seq pipelines and NGS-based neoantigen discovery workflows.


Applied AI, data science & programming
Python (NumPy, SciPy, pandas) matplotlib/seaborn/plotly machine learning (scikit-learn) applied AI (OpenAI and Gemini APIs) R (Bioconductor) Markdown & LaTeX SQL full-stack Django HTML/CSS/JS/D3 Qt for Python (PySide6) Bash Powershell C++ MATLAB

Bioinformatics, cloud & research operations
(sc)RNA-Seq pipelines NGS-based neoantigen discovery PyMOL Google Cloud Platform (GCP) Jupyter GitLab/GitHub Docker OpenBIS advanced Excel (VBA/Python) Power BI FlowJo Prism GeneSpring

Hardware & systems engineering
electronics (integrated circuits, microprocessors) microcontrollers (Arduino, RPi) MicroPython Linux SysAdmin (Ubuntu, Kali) infrastructure optimization

Professional development and strategic certifications
Cloud computing & applied AI (2023—2026)

Advanced mathematics & data science (2017—2023)

Quantitative biology & bioinformatics (2017—2023)

Scientific foundation and regulatory leadership (2004—2017)
Regulatory & management: Accredited Study Director (LTK Module 2) (University of Zurich) SME Instrument Training (Euresearch) Création d'entreprises innovantes (Université de Montpellier) Technical masterclass: Chemistry for higher education (Université de Liège) Human Histology (Université de Liège) Animal Experimentation & Surgery (Université Strasbourg I) Multicolor Cytometry (AFC Paris) Proteomics (IBMC) Confocal Microscopy (IBMP)

SCIENTIFIC IMPACT, PUBLICATIONS AND INTELLECTUAL PROPERTY (IP)

Demonstrated research excellence with an h-index of 19, 24 peer-reviewed publications, and 2 international patents; formally accredited for the French Research Tax Credit (CIR) 2025—2027 and officially recognized by the French Ministry of Higher Education & Research.

Publications
  1. Young LE, Schnieke AE, McCreath KJ, Wieckowski S, Konfortova G, Fernandes K, Ptak G, Kind AJ, Wilmut I, Loi P, Feil R. Conservation of IGF2-H19 and IGF2R imprinting in sheep: effects of somatic cell nuclear transfer. Mech Dev (2003) 120:1433-1442. doi: 10.1016/j.mod.2003.09.006
  2. Wu W, Wieckowski S, Pastorin G, Benincasa M, Klumpp C, Briand JP, Gennaro R, Prato M, Bianco A. Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes. Angew Chem Int Ed Engl (2005) 44:6358-6362. doi: 10.1002/anie.200501613
  3. Wieckowski S, Fournel S, Sun W, Trouche N, Dumortier H, Bianco A, Chaloin O, Habib M, Peter JC, Schneider P, Vray B, Toes RE, Offringa R, Melief CJ, Hoebeke J, Guichard G. C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. Nat Chem Biol (2005) 1:377-382. doi: 10.1038/nchembio746 – Research Highlights: Drug Discovery: Immune booster. Nature (2005) 438:132. Immunotherapy: TNFR superfamily trimers. Nat Rev Drug Discov (2006) 5:1
  4. Pastorin G, Wu W, Wieckowski S, Briand JP, Kostarelos K, Prato M, Bianco A. Double functionalization of carbon nanotubes for multimodal drug delivery. Chem Commun (Camb) (2006) 21:1182-1184. doi: 10.1039/b516309a – Recognized as within the top 50 articles published in 2006 in Chem Commun
  5. Bianco A, Fournel S, Wieckowski S, Hoebeke J, Guichard G. Solid-phase synthesis of CD40L mimetics. Org Biomol Chem (2006) 4:1461-1463. doi: 10.1039/b601528j
  6. Kostarelos K, Lacerda L, Pastorin G, Wu W, Wieckowski S, Luangsivilay J, Godefroy S, Pantarotto D, Briand JP, Muller S, Prato M, Bianco A. Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat Nanotech (2007) 2:108-113. doi: 10.1038/nnano.2006.209
  7. Wieckowski S, Trouche N, Chaloin O, Guichard G, Fournel S, Hoebeke J. Cooperativity in the interaction of synthetic CD40L mimetics with CD40 and its implication in cell signaling. Biochem (2007) 46:3482-3493. doi: 10.1021/bi602434a
  8. Habib M, Chamekh M, Rivas MN, Wieckowski S, Sun W, Bianco A, Trouche N, Chaloin O, Dumortier H, Goldman M, Guichard G, Fournel S, Vray B. Small molecule CD40L mimetics promote control of parasitemia by enhancing CD8+ cells production of interferon-γ during experimental Trypanosoma cruzi infection. J Immunol (2007) 178:6700-6704. doi: 10.4049/jimmunol.178.11.6700
  9. Trouche N, Wieckowski S, Sun W, Chaloin O, Briand JP, Hoebeke J, Fournel S, Guichard G. Small trivalent architectures mimicking homotrimers of the TNF superfamily member CD40L: delineating the relationship between structure and effector function. JACS (2007) 129:13480-13492. doi: 10.1021/ja073169m
  10. Rich LR, Papalia GA, Flynn PJ… Wieckowski S… Myszka DG. A global benchmark study using affinity-based biosensors. Anal Biochem (2009) 386:194-216. doi: 10.1016/j.ab.2008.11.021
  11. Partidos CD, Hoebeke J, Wieckowski S, Chaloin O, Bianco A, Moreau E, Briand JP, Desgranges C, Muller S. Immunomodulatory consequences of ODN CpG-polycation complexes. Methods (2009) 49:328-333. doi: 10.1016/j.ymeth.2009.03.005
  12. Jandus C, Bioley G, Dojcinovic D, Derré L, Baitsch L, Wieckowski S, Rufer N, Kwok WW, Tiercy JM, Luescher IF, Speiser DE, Romero P. Tumor antigen specific regulatory CD4 T-cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res (2009) 69:8085-8093. doi: 10.1158/0008-5472.CAN-09-2226
  13. Wieckowski S, Baumgaertner P, Corthésy P, Voelter V, Romero P, Speiser DE, Rufer N. Fine structural variations of αβTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol (2009) 183:5397-5406. doi: 10.4049/jimmunol.0901460
  14. Iancu EM, Baumgaertner P, Wieckowski S, Speiser DE, Rufer N. Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination. J Biomed Biotech (2011) 2011:452606. doi: 10.1155/2011/452606
  15. Baitsch L, Baumgaertner P, Devêvre E, Raghav SK, Legat A, Barba L, Wieckowski S, Bouzourene H, Deplanke B, Romero P, Rufer N, Speiser DE. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J Clin Invest (2011) 121:2350-2360. doi: 10.1172/JCI46102
  16. Wieckowski S, Speiser DE, Gupta B, Iancu EM, Baumgaertner P, Baitsch L, Michielin O, Romero R, Rufer N. Single cell analysis reveals similar functional competence of dominant and non-dominant CD8 T-cell clonotypes. Proc Natl Acad Sci USA (2011) 108:15318-15323. doi: 10.1073/pnas.1105419108
  17. Leimgruber A, Ferber M, Irving M, Wieckowski S, Hussain-Kahn H, Derré L, Rufer N, Zoete V, Michielin O. TCRep 3D: an automated in silico approach to study the structural properties of TCR repertoires. PloS ONE (2011) 6: e26301. doi: 10.1371/journal.pone.0026301
  18. Lövgren T, Baumgaertner P, Wieckowski S, Devêvre E, Guillaume P, Luescher I, Rufer N, Speiser DE. Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific T cells after vaccination with low peptide dose. Cancer Immunol Immunother (2012) 61(6):817. doi: 10.1007/s00262-011-1140-1
  19. Gupta B, Iancu EM, Gannon PO, Wieckowski S, Baitsch L, Speiser DE, Rufer N. Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T cells depends on antigen specificity and differentiation. J Immunother (2012) 35(6):488. doi: 10.1097/CJI.0b013e31826183a7
  20. Wieckowski S, Hemmerle T, Savic Prince S, Dolder Schlienger B, Hillinger S, Neri D, Zippelius A. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung. Lung Cancer (2015) 88(1):9. doi: 10.1016/j.lungcan.2015.01.019
  21. Gannon PO, Wieckowski S, Baumgaertner P, Hebeisen M, Allard M, Speiser DE, Rufer N. Quantitative TCR avidity assessment by NTAmers reveals melanoma antigen-specific T cell repertoires enriched for high functional competence. J Immunol (2015) 195:356. doi: 10.4049/jimmunol.1403145
  22. Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer H, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P. A phase 1 trial extension to assess immunologic efficacy and safety of prime – boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. OncoImmunology (2018) 7(4):e1303584. doi: 10.1080/2162402X.2017.1303584
  23. Kashyap AS, Fernandez-Rodriguez L, Zhao Y, Monaco G, Trefny MP, Yoshida N, Martin K, Sharma A, Olieric N, Shah P, Stanczak M, Kirchhammer N, Park SM, Wieckowski S, Laubli H, Zagani R, Kasenda B, Steinmetz MO, Reinecker HC, Zippelius A. GEF-H1 signaling upon microtubule destabilization is required for dendritic cell activation and specific anti-tumor responses. Cell Rep (2019) 28(13):3367. doi: 10.1016/j.celrep.2019.08.057
  24. Wieckowski S, Avenal C, Orjalo AV, Gygax D, and Cymer F. Toward a better understanding of bioassays for the development of biopharmaceuticals by exploring the structure-antibody-dependent cellular cytotoxicity relationship in human primary cells. Front Immunol (2020) 11: 552596. doi: 10.3389/fimmu.2020.552596

Books
  1. Wieckowski S. Intuitive Biostatistics with Python: A Python Companion Guide for Life Sciences Professionals. Oxford University Press (2026). DOI: 10.1093/oso/9780197845028.001.0001. Print ISBN: 9780197845028 | Online ISBN: 9780197845882.

Patents
  1. Guichard G, Fournel S, Chaloin O, Trouche N, Wieckowski S, Hoebeke J. Novel multimeric CD40 ligands, method for preparing same and use thereof for preparing drugs. Brevet Français 04/13331, déposant CNRS (15/12/2004). International Application PCT/FR2005/03146 (15/12/2005). International Publication WO/2006/064133 (22/06/2006)
  2. Guichard G, Fournel S, Trouche N, Wieckowski S. Novel multimeric molecules, a process for preparing the same and the use thereof for manufacturing medical drugs. Brevet Français 07/00809, déposant CNRS (05/02/2007). International Application PCT/FR2008/000129 (04/02/2008). International Publication WO/2008/110695 (18/09/2008)

Communications (selection)
  • Wieckowski S, Avenal C, Orjalo AV, Gygax D, and Cymer F. A better understanding of bioassays – comparison of binding assays, reporter gene assays and primary cell-based assays of glycoengineered monoclonal antibodies. BEBPA’s Virtual 2021 EUR Bioassay Conference. Oral presentation
  • Wieckowski S, Podola L, Kobl I, Smetak H, Springer M, Nugues AL, Slos P, Broadmeadow A, Chesher C, Adda Berkane A, Wei M, Breiner K, Meichle A, Breiner K, Mansour M, Beckhove P, Lubenau H. Modulating T cell immunity in tumors by targeting tumor-associated antigens, PD-L1 and neoantigens using a versatile live attenuated oral Salmonella DNA vaccination platform. AACR Annual Meeting, Chicago, 2018. Poster 733
  • Wieckowski S. Non-clinical safety, immunogenicity and antitumor efficacy of live attenuated Salmonella Typhimurium based oral T-cell vaccines. ASGCT 20th Annual Meeting, Washington DC, 2017. Oral presentation
  • Wieckowski S, Podola L, Springer M, Broadmeadow A, Stevens P, Chesher C, Adda Berkane A, Wei M, Kobl I, Meichle A, Beckhove P, Breiner K, Lubenau H. Non-clinical safety, immunogenicity and antitumor efficacy of live attenuated Salmonella Typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m. AACR Annual Meeting, Washington DC, 2017. Poster 4558
  • Wieckowski S. Using the immune system to treat cancer – Could we cure cancer in the next ten years? European Health Science Match. Heidelberg, 2016. Oral presentation
  • Wieckowski S. Therapeutic synergism of a novel tumor stroma-targeted IL-2-variant immunocytokine with standard-of- care anti-cancer therapeutics and immunomodulatory antibodies in the genetically engineered KP mouse model of non-small cell lung cancer. Roche Symposium of the Roche Postdoc Fellowship Program. Basel, 2013. Oral presentation
  • Wieckowski S, Müller P, Freimoser-Grundschober A, Savic S, Fink Y, Karanikas V, Umana P, Pisa P, Klein C, Zippelius A. Therapeutic synergism of a novel tumor stroma-targeted IL-2-variant immunocytokine with standard-of-care anti-cancer therapeutics and immunomodulatory antibodies in the genetically engineered KP mouse model of non-small cell lung cancer. Roche Symposium of the Roche Postdoc Fellowship Program. Penzberg, 2012. Poster RPF ID 216
  • Wieckowski S, Baumgaertner P, Corthésy P, Voelter V, Romero R, Speiser D, Rufer N. Characterization of CD8+ T cell responses induced by vaccination with Melan-A peptides in melanoma patients. Role of Inflammation in Oncogenesis and Immune Escape in Cancer joint Keystone Symposia, Keystone, CO, 2010. Poster J5-338
  • Wieckowski S, Baumgaertner P, Corthésy P, Voelter V, Romero R, Speiser D, Rufer N. Molecular characterization of CD8+ T cell responses in melanoma patients following therapeutic peptide vaccination. 4e Journée Scientifiques du Cancéropôle Lyon Auvergne Rhône-Alpes, Archamps (France), 2009. Poster P70. Best Poster Award
  • Wieckowski S, Baumgaertner P, Corthésy P, Voelter V, Romero R, Speiser D, Rufer N. CD8 T cell responses in melanoma patients following therapeutic peptide vaccination. 1st Swiss Immunotherapy Symposium, Lausanne, 2009. Oral presentation
  • Wieckowski S, Trouche N, Hoebeke J, Guichard G, Fournel S. Application of functional small synthetic CD40L mimetics to lymphoma therapy. 1st joint meeting of European National Societies of Immunology, 16th European Congress of Immunology. Paris, 2006. Poster PD-3918
  • Wieckowski S, Trouche N, Sun W, Chaloin O, Hoebeke J, Guichard G, Fournel S. Improvements of small synthetic CD40L mimetics and their effects on cell signaling. MipTec – the 9th Leading European Drug Discovery Event. Basel, 2006. Poster P89
  • Wieckowski S, Trouche N, Chaloin O, Bianco A, Hoebeke J, Dumortier H, Guichard G, Fournel S. A synthetic multimeric ligand of CD40 is able to mimic effector functions of the natural CD40L. Congrès Annuel de la Société Française d’Immunologie. Paris, 2004. Poster P50

Congress Abstracts
  • Wieckowski S, Podola L, Smetak H, Nugues AL, Slos P, Berkane AA, Wei M, Breiner K, Meichle A, Beckhove P, Mansour M, Lubenau H. Modulating T cell immunity in tumors by targeting PD-L1 and neoantigens using a live attenuated oral Salmonella platform. Cancer Res (2018) 78(13 Supplement):733-733
  • Wick W, Wick A, Sahm F, Riehl D, von Deimling A, Bendszus M, Kickingereder P, Bonekamp D, Beckhove P, Schmitz-Winnenthal FH, Jungk C, Wieckowski S, Podola L, Herold-Mende C, Unterberg A, Platten MJ. VXM01 phase I study in patients with progressive glioblastoma: Final results. J Clin Oncol (2018) 36(15_suppl):2017-2017
  • Wieckowski S, Smetak H, Kobl I, Podola L, Nugues AL, Slos P, Berkane AA, Wei M, Breiner K, Meichle A, Mansour M, Schroff M, Beckhove P, Lubenau H. Live attenuated oral Salmonella platform for effective T- and B-cell targeting of PD-L1. J Clin Oncol (2018) 36(5_suppl):74-74
  • Wieckowski S, Podola L, Springer M, Kobl I, Koob Z, Mignard C, Berkane AA, Wei M, Meichle A, Breiner K, Schroff M, Beckhove P, Lubenau H. Immunogenicity and antitumor efficacy of live attenuated Salmonella typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m. Cancer Res (2017) 77(13S):Abstract nr 4558
  • Wick W, Wick A, Nowosielski M, Sahm F, Riehl D, Arzt M, von Deimling A, Bendszus M, Kickingereder P, Bonekamp D, Beckhove P, Schmitz-Winnenthal FH, Jungk C, Wieckowski S, Herold-Mende C, Lubenau H, Unterberg A, Platten MJ. VXM01 phase I study in patients with resectable progression of a glioblastoma. J Clin Oncol (2017) 35(15_suppl):2061-2061
  • Wieckowski S, Springer M, Podola L, Broadmeadow A, Stevens P, Chesher CJ, Berkane AA, Wei M, Meichle A, Beckhove P, Breiner K, Lubenau H. Non-clinical safety and antitumor efficacy of live attenuated Salmonella typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m. Eur J Cancer (2016) 69:S106
  • Guichard G, Trouche N, Wieckowski S, Sun W, Chaloin O, Bianco A, Hoebeke J, Schneider P, Fournel S. Rationally designed multivalent architectures for mimicking homotrimers of CD40L, a member of the TNF superfamily. Peptides for Youth: The Proceedings of the 20th American Peptide Symposium, Montreal (Canada), 2007. Adv Exp Med Biol (2009) 611:355-357

Peer-Reviewing Authority
Active reviewer for Journal for ImmunoTherapy of Cancer, Cancer Immunology Immunotherapy, Journal of Cancer Research and Clinical Oncology, Cancers, Vaccines, Viruses, Biomedicines, Immuno, Journal of Clinical Medicine, Marine Drugs, Genes, Biomolecules, and International Journal of Molecular Sciences.

Detailed records available via Web of Science and ORCID.

Grants & Fellowships
  • Freiwillige Akademische Gesellschaft (FAG) Grant (2013)
  • Roche Postdoctoral Fellowship (RPF) Extension (2013)
  • Wilhelm Sander-Stiftung Fellowship (2010)
  • ANRS Research Grant & Post-doctoral Fellowship (2007)
  • Fondation pour la Recherche Médicale (FRM) Fellowship (2007)